Findings from a Phase I trial of autologous SVF therapy in ALS

Zenglin Cai, PhD, Nanjing Medical University, Nanjing, China, discusses a Phase I trial (ChiCTR2400091754) exploring autologous stromal vascular fraction (SVF) therapy in amyotrophic lateral sclerosis (ALS). Dr Cai shares key findings on the efficacy and safety, demonstrating that SVF therapy is safe and effective in these patients. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.